allopurinol sandoz 100 mg tabletes
sandoz d.d., slovenia - allopurinols - tablete - 100 mg
allopurinol sandoz 300 mg tabletes
sandoz d.d., slovenia - allopurinols - tablete - 300 mg
allopurinol orifarm 100 mg tabletes
orifarm healthcare a/s, denmark - allopurinols - tablete - 100 mg
allopurinol orifarm 300 mg tabletes
orifarm healthcare a/s, denmark - allopurinols - tablete - 300 mg
allopurinol accord 100 mg tabletes
accord healthcare b.v., netherlands - allopurinols - tablete - 100 mg
allopurinol accord 300 mg tabletes
accord healthcare b.v., netherlands - allopurinols - tablete - 300 mg
allopurinol eg 100 mg tabletes
eg labo - laboratoires eurogenerics, france - allopurinols - tablete - 100 mg
allopurinol eg 300 mg tabletes
eg labo - laboratoires eurogenerics, france - allopurinols - tablete - 300 mg
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiski līdzekļi - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
all-c (2016.) tablete
thompson & capper ltd - tablete